How Long Is Too Long?

Readers discuss the varied amounts of time they’ve waited for journals to respond to or act on their concerns regarding published papers.

Written byTracy Vence
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, DEE SPEEDAs long as journals have existed, so too have letters to the editor. But such correspondence is often kept private, in particular for cases discussing perceived errors or, worse still, potential research misconduct. With the rise of post-publication peer review fora such as the privately run website PubPeer, which allows users to comment on published papers with varied degrees of anonymity, and the publicly funded PubMed Commons, where commenters are identified by name and institution, researchers are starting to move such discussion out into the open.

Still, it’s unclear whether the journals are paying much attention when articles they’ve published are questioned online. The Scientist asked a handful of journals whether they monitor sites like PubPeer, receiving a mixed response: yes, some editors do scan the web for comments on papers they’ve published, but doing so—at this point—is typically not formal policy. So it’s still unclear whether discussing problems with published papers openly online is any better than sending an unanswered letter to the editor.

The Scientist asked readers on Twitter how long they’ve waited to hear from journals they’ve contacted with questions or comments about suspected flaws in published papers. The responses, while not necessarily representative of journal correspondence overall, were not promising.

@PSBROOKES: “almost 3 years”

@MicrobiomDigest: “Over a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies